Nexalin Technology (NXL) Stock Price, News & Analysis

Company Overview

Nexalin Technology, Inc. is a U.S.-based medical device company specializing in noninvasive neuromodulation therapies for mental health conditions. The company develops and markets the Nexalin® medical device platform, which delivers proprietary alternating current waveforms to targeted areas of the brain through forehead-mounted electrodes. Its technology is designed to modulate neural activity without pharmaceuticals, positioning the company within the growing field of digital therapeutics and neurostimulation.

The Nexalin device has received U.S. Food and Drug Administration 510(k) clearance for the treatment of generalized anxiety disorder and is marketed to healthcare providers, including psychiatrists, primary care physicians and behavioral health clinics. The therapy protocol typically involves a series of short, in-office treatment sessions during which patients remain awake and alert. Nexalin also supports ongoing clinical research to explore additional applications such as depression and stress-related conditions.

Headquartered in the United States, Nexalin Technology distributes its devices and training programs through a network of authorized dealers and directly to healthcare institutions. The company focuses on expanding adoption among mental health professionals by combining its regulatory-cleared device with physician training, clinical support services and patient education materials. As interest grows in nonpharmacological approaches to mental health, Nexalin aims to broaden its footprint across outpatient clinics and other care settings nationwide.

Key Stats

• Today's Range: $0.48 to $0.54
• 50-Day Range: $0.32 to $0.61
• 52-Week Range: $0.31 to $2.00
• Volume: 503,191 shs
• Average Volume: 1.38 million shs
• Market Capitalization: $10.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Nexalin Technology Stock Analysis - MarketRank™

Nexalin Technology scored higher than 2% of companies evaluated by MarketBeat, and ranked 291st out of 298 stocks in the business services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Nexalin Technology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Nexalin Technology has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nexalin Technology is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nexalin Technology is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nexalin Technology has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.95% of the float of Nexalin Technology has been sold short.

Short Interest Ratio / Days to Cover

Nexalin Technology has a short interest ratio ("days to cover") of 6.12.

Change versus previous month

Short interest in Nexalin Technology has recently increased by 5.97%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nexalin Technology does not currently pay a dividend.

Dividend Growth

Nexalin Technology does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Nexalin Technology this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for NXL on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Nexalin Technology to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nexalin Technology insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.26% of the stock of Nexalin Technology is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

0.65% of the stock of Nexalin Technology is held by institutions.

Company Calendar

• Last Earnings: 5/08/2026
• Today: 6/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Business Services
• Industry: Technology Services
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NXL
• CIK: 1527352
• Web: www.nexalin.com
• Phone: 832-260-0222
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.22 million
• Net Margins: -3,018.12%
• Pretax Margin: -3,018.48%
• Return on Equity: -191.88%
• Return on Assets: -166.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.07
• Quick Ratio: 3.85

Sales & Book Value

• Annual Sales: $300 thousand
• Price / Sales: 35.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 2.62

Miscellaneous

• Outstanding Shares: 20,580,000
• Free Float: 15,383,000
• Market Cap: $10.78 million
• Optionable: Not Optionable
• Beta: 3.80